• Mashup Score: 0
    Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad - 1 year(s) ago

    Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial’s primary endpoint was…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ4Wa5 https://t.co/T3TP4AE6OQ

  • Mashup Score: 0
    Wolters Kluwer Health - 1 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      Adding #olaparib to standard-of-care #abiraterone shows a trend toward improvement in overall #survival by more than 7 months in the treatment of metastatic castrate-resistant #prostatecancer, according to final OS results of the #PROpel trial: https://t.co/tuGD7Thn6c #mCRPC https://t.co/FaRRAKY2NP

  • Mashup Score: 0
    Wolters Kluwer Health - 1 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      Adding #olaparib to standard-of-care #abiraterone shows a trend toward improvement in overall #survival by more than 7 months in the treatment of metastatic castrate-resistant #prostatecancer, according to final OS results of the #PROpel trial: https://t.co/tuGD7Thn6c #mCRPC https://t.co/uJEo6q0e04

  • Mashup Score: 0
    Wolters Kluwer Health - 1 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      Adding #olaparib to standard-of-care #abiraterone shows a trend toward improvement in overall #survival by more than 7 months in the treatment of metastatic castrate-resistant #prostatecancer, according to final OS results of the #PROpel trial: https://t.co/tuGD7ThUVK #mCRPC https://t.co/SLwq0HcGJ9

  • Mashup Score: 2
    Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad - 1 year(s) ago

    Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial’s primary endpoint was…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ5tZD https://t.co/k4PNUkWGVk

  • Mashup Score: 16
    Program | ASCO Genitourinary Cancers Symposium - 1 year(s) ago

    Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with…

    Source: conferences.asco.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncBrothers
      OncBrothers

      Day 1 #GU23 #ProstateCacer Highlights #CommunityOncology 1. #TALAPRO2: mCRPC PARPi 1L @neerajaiims  2. #TRITON3: mCRPC PARPi 2L @AlanBryce9  3. #ARASENS update Dara+Doce 1L 4. #PROPEL update PARPi 1L https://t.co/ma9PAah1Jm @ASCO #OncEd #MedEd @OncoAlert #GUSM #MedTwitter

  • Mashup Score: 0
    Sign up - 1 year(s) ago

    UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

    Source: www.urotoday.com
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Looking forward to the presentation from Noel Clarke @TheChristieNHS - Final OS in the #PROpel trial. Feb, 16th during the Advanced #ProstateCancer: New Targets, New Drugs, New Victories session at @ASCO #GU23. Don't miss written coverage on UroToday > https://t.co/Idtgyf6FSV https://t.co/PuGzWucjmJ

Load More